These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6666265)

  • 1. [Histopathology and clinical course of chronic, myeloproliferative diseases].
    Georgii A
    Verh Dtsch Ges Pathol; 1983; 67():214-34. PubMed ID: 6666265
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic myeloproliferative diseases].
    Verh Dtsch Ges Pathol; 1983; 67():214-75. PubMed ID: 6666266
    [No Abstract]   [Full Text] [Related]  

  • 3. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)].
    Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S
    Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769
    [No Abstract]   [Full Text] [Related]  

  • 5. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
    Haferlach T; Kern W; Schnittger S; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating progenitor cells in chronic myeloproliferative diseases.
    Rosti V; Massa M
    Haematologica; 2006 Nov; 91(11):1445-7. PubMed ID: 17082003
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical course and terminal features of chronic myeloproliferative syndrome].
    Yonemitsu H
    Rinsho Ketsueki; 1988 Jul; 29(7):950-9. PubMed ID: 3184481
    [No Abstract]   [Full Text] [Related]  

  • 8. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J
    Am J Clin Pathol; 2009 Aug; 132(2):261-80. PubMed ID: 19605821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and histological studies of fundus oculi changes in malignant hematologic diseases].
    Klatt A; Herrmann G; Klatt R
    Dtsch Gesundheitsw; 1971 May; 26(21):967-70. PubMed ID: 5117089
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: overview of chronic myeloproliferative disorders.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):1-2. PubMed ID: 9930549
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
    Thiele J; Kvasnicka HM; Orazi A
    Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
    Rudzki Z; Papla B; Stachura J
    Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
    Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
    Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte function in chronic myeloproliferative disorders.
    Wolach B; Gavrieli R; Manor Y; Lishner M
    Blood Cells Mol Dis; 1998 Dec; 24(4):544-51. PubMed ID: 9887281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders.
    Cella G; Randi ML; Sbarai A; Bauer KA; Barzega S; Rosenberg RD
    Haematologica; 2002 Jun; 87(6):671-2. PubMed ID: 12031932
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypocholesterolemia: an assessment of activity in myeloproliferative diseases.
    Giardina MG; Matarazzo M; Varriale A; Battipaglia G; Cigolari S
    Panminerva Med; 1988; 30(1):13-5. PubMed ID: 3419847
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Skin microangiopathy in myeloproliferative diseases].
    Valdés EF; Herrero MV; Calb I; Schiffelbein M
    Rev Clin Esp; 1978 Oct; 151(1):11-3. PubMed ID: 740965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.